Mališić, Emina

Link to this page

Authority KeyName Variants
592a93f0-ca74-4c53-9a4d-3660f4cbb93e
  • Mališić, Emina (2)
Projects
No records found.

Author's Bibliography

XRCC3 Thr241Met gene polymorphism and acute radiotherapy induced toxicity for prostate cancer

Mališić, Emina; Petrović, Nina; Nikitović, Marina

(Elsevier, 2022)

TY  - CONF
AU  - Mališić, Emina
AU  - Petrović, Nina
AU  - Nikitović, Marina
PY  - 2022
PY  - S1
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12422
AB  - Purpose or Objective About half of all prostate cancer (PCa) patients receive radiotherapy (RT) either as single curative treatment or as adjuvant/salvage treatment after radical prostatectomy. However, RT is associated with a spectrum of side effects (toxicity) in the surrounding normal tissues. Acute toxicity occurs within 90 days of treatment, is usually transient and affects skin and mucosa of bladder and intestine resulting in dermatitis, cystitis or diarrhea. XRCC3 gene encodes for protein that is involved in homologous recombination repair of double-strand breaks created by ionizing radiation. Disruption of these pathways has the potential to affect the normal tissue response to RT. The T variant of XRCC3 Thr241Met single nucleotide polymorphisms (SNP) in exon 7 (C>T, rs861539) was reported to be associated with elevated levels of DNA adducts, chromosomal deletions, sensitivity to ionizing radiation and cross-linking agents. The aim of this study was to examine association between this SNP and RT-induced normal tissue toxicity in PCa patients. Materials and Methods Eighty one patients who had a histologically confirmed localized or locally advanced PCa were included in the study. Patients were treated with 3DC RT (n=70) or ARC RT (n=11) with radical (72 Gy)(47 patients) or postoperative/salvage (66 Gy)(34 patients) RT without previous hormonal therapy. DNA from peripheral blood mononuclear cells was extracted by salting out method. XRCC3 Thr241Met SNP was determined by PCR-RFLP analysis. The restriction fragments were separated on 2100 Bioanalyzer using DNA 1000 kit. The differences in the distribution of genotypes of XRCC3 Thr241Met between patients with or without acute RT-induced genitourinary (GU) or gastrointestinal (GI) toxicity were tested by χ2 and Fisher’s exact test. P values ≤ 0.05 were considered statistically significant, while p values between 0.1 and 0.05 were pointed out as a statistical trend. Data were analyzed by SigmaStat 3.5. Results The acute GI toxicity appeared in 100%, 94.6% and 81.8% of ThrThr, ThrMet and MetMet PCa patients, raspectivelly. There was the statistical trend towards higher acute GU toxicity in carriers of Thr variant (ThrThr plus ThrMet) vs. MetMet (p=0.087) as well as ThrThr vs. MetMet (p=0.058). For acute GI toxicity, there was a similar distribution in genotypes: 90.9%, 91.9%, 90.9% for ThrThr, ThrMet, MetMet, respectively. PCa patients with ThrThr genotype had higher rate of acute GU toxicity grade ≥2 (45.5%) than ThrMet (28.6%) and MetMet (22.2%) while in GI toxicity MetMet had higher rate of grade ≥2 (40%) than ThrThr (23.3%) and ThrMet (23.5%) but without statistical significance. Conclusion The obtained data indicate that Thr variant of XRCC3 Thr241Met SNP is related to acute GU toxicity. Grade ≥2 acute GU toxicity could be associated with ThrThr while GI toxicity with MetMet genotype. Further study on larger group is necessary to confirm this date and to clarify mechanism underlying this observation.
PB  - Elsevier
C3  - ESTRO 2022 : Radiotherapy & Oncology : Journal of the European SocieTy for Radiotherapy and Oncology : Book of abstracts
T1  - XRCC3 Thr241Met gene polymorphism and acute radiotherapy induced toxicity for prostate cancer
VL  - 170
SP  - S1621
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12422
ER  - 
@conference{
author = "Mališić, Emina and Petrović, Nina and Nikitović, Marina",
year = "2022, S1",
abstract = "Purpose or Objective About half of all prostate cancer (PCa) patients receive radiotherapy (RT) either as single curative treatment or as adjuvant/salvage treatment after radical prostatectomy. However, RT is associated with a spectrum of side effects (toxicity) in the surrounding normal tissues. Acute toxicity occurs within 90 days of treatment, is usually transient and affects skin and mucosa of bladder and intestine resulting in dermatitis, cystitis or diarrhea. XRCC3 gene encodes for protein that is involved in homologous recombination repair of double-strand breaks created by ionizing radiation. Disruption of these pathways has the potential to affect the normal tissue response to RT. The T variant of XRCC3 Thr241Met single nucleotide polymorphisms (SNP) in exon 7 (C>T, rs861539) was reported to be associated with elevated levels of DNA adducts, chromosomal deletions, sensitivity to ionizing radiation and cross-linking agents. The aim of this study was to examine association between this SNP and RT-induced normal tissue toxicity in PCa patients. Materials and Methods Eighty one patients who had a histologically confirmed localized or locally advanced PCa were included in the study. Patients were treated with 3DC RT (n=70) or ARC RT (n=11) with radical (72 Gy)(47 patients) or postoperative/salvage (66 Gy)(34 patients) RT without previous hormonal therapy. DNA from peripheral blood mononuclear cells was extracted by salting out method. XRCC3 Thr241Met SNP was determined by PCR-RFLP analysis. The restriction fragments were separated on 2100 Bioanalyzer using DNA 1000 kit. The differences in the distribution of genotypes of XRCC3 Thr241Met between patients with or without acute RT-induced genitourinary (GU) or gastrointestinal (GI) toxicity were tested by χ2 and Fisher’s exact test. P values ≤ 0.05 were considered statistically significant, while p values between 0.1 and 0.05 were pointed out as a statistical trend. Data were analyzed by SigmaStat 3.5. Results The acute GI toxicity appeared in 100%, 94.6% and 81.8% of ThrThr, ThrMet and MetMet PCa patients, raspectivelly. There was the statistical trend towards higher acute GU toxicity in carriers of Thr variant (ThrThr plus ThrMet) vs. MetMet (p=0.087) as well as ThrThr vs. MetMet (p=0.058). For acute GI toxicity, there was a similar distribution in genotypes: 90.9%, 91.9%, 90.9% for ThrThr, ThrMet, MetMet, respectively. PCa patients with ThrThr genotype had higher rate of acute GU toxicity grade ≥2 (45.5%) than ThrMet (28.6%) and MetMet (22.2%) while in GI toxicity MetMet had higher rate of grade ≥2 (40%) than ThrThr (23.3%) and ThrMet (23.5%) but without statistical significance. Conclusion The obtained data indicate that Thr variant of XRCC3 Thr241Met SNP is related to acute GU toxicity. Grade ≥2 acute GU toxicity could be associated with ThrThr while GI toxicity with MetMet genotype. Further study on larger group is necessary to confirm this date and to clarify mechanism underlying this observation.",
publisher = "Elsevier",
journal = "ESTRO 2022 : Radiotherapy & Oncology : Journal of the European SocieTy for Radiotherapy and Oncology : Book of abstracts",
title = "XRCC3 Thr241Met gene polymorphism and acute radiotherapy induced toxicity for prostate cancer",
volume = "170",
pages = "S1621",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12422"
}
Mališić, E., Petrović, N.,& Nikitović, M.. (2022). XRCC3 Thr241Met gene polymorphism and acute radiotherapy induced toxicity for prostate cancer. in ESTRO 2022 : Radiotherapy & Oncology : Journal of the European SocieTy for Radiotherapy and Oncology : Book of abstracts
Elsevier., 170, S1621.
https://hdl.handle.net/21.15107/rcub_vinar_12422
Mališić E, Petrović N, Nikitović M. XRCC3 Thr241Met gene polymorphism and acute radiotherapy induced toxicity for prostate cancer. in ESTRO 2022 : Radiotherapy & Oncology : Journal of the European SocieTy for Radiotherapy and Oncology : Book of abstracts. 2022;170:S1621.
https://hdl.handle.net/21.15107/rcub_vinar_12422 .
Mališić, Emina, Petrović, Nina, Nikitović, Marina, "XRCC3 Thr241Met gene polymorphism and acute radiotherapy induced toxicity for prostate cancer" in ESTRO 2022 : Radiotherapy & Oncology : Journal of the European SocieTy for Radiotherapy and Oncology : Book of abstracts, 170 (2022):S1621,
https://hdl.handle.net/21.15107/rcub_vinar_12422 .

Association between TGFB1 C-509T polymorphism and acute toxicity after radiotherapy for prostate cancer

Mališić, Emina; Petrović, Nina; Nikitović, Marina; Stanojković, Tatjana

(Belgrade : Serbian Association for Cancer Research (SDIR), 2021)

TY  - CONF
AU  - Mališić, Emina
AU  - Petrović, Nina
AU  - Nikitović, Marina
AU  - Stanojković, Tatjana
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12415
AB  - Background: Radiotherapy (RT) for prostate cancer (PCa) is associated with a spectrum of side effects (toxicity) in the surrounding normal tissues. TGFB1 is a key cytokine associated with inflammation and fibrosis, but its role in acute toxicity is unclear. The presence of T allele at −509 bp of the promoter region of TGFB1 gene is related to higher concentrations of TGFB1 than C allele. We aimed to investigate association between C-509T polymorphism (rs1800469) and RT-induced acute toxicity. Patients and methods: Eighty six patients who had a localized or locally advanced PCa were treated with radical (72 Gy)(n=49) or postoperative/salvage (66 Gy)(n=37) RT without previous hormonal therapy. TGFB1 C-509T was determined by PCR-RFLP analysis on DNA from PBMC. The differences in the distribution of genotypes between patients with or without acute genitourinary (GU) or gastrointestinal (GI) toxicity were tested by χ2 and Fisher’s exact test. P values ≤0.05 were considered statistically significant. The genotype-specific associations with toxicity were estimated as odds ratios (OR) with 95% confidence intervals (CIs) for dominant, recessive, codominant and overdominant genetic model. Results: Heterozygote carriers of TGFB1 C-509T had statistically significant lower rate of acute GU and GI toxicity then homozygotes (CC plus TT) (p=0.048; p=0.047). Additionally, the OR indicated lower risk for acute toxicity development in heterozygote than homozygote patients (OR (95%CI) were: 0.12 (0.01- 1.11) for GU and 0.19 (0.03- 1.02) for GI). Conclusion: The obtained data indicate that CT genotype of TGFB1 C-509T could be potential biomarkers of lower risk for acute RT-induced toxicity.
PB  - Belgrade : Serbian Association for Cancer Research (SDIR)
C3  - SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts
T1  - Association between TGFB1 C-509T polymorphism and acute toxicity after radiotherapy for prostate cancer
SP  - 60
EP  - 60
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12415
ER  - 
@conference{
author = "Mališić, Emina and Petrović, Nina and Nikitović, Marina and Stanojković, Tatjana",
year = "2021",
abstract = "Background: Radiotherapy (RT) for prostate cancer (PCa) is associated with a spectrum of side effects (toxicity) in the surrounding normal tissues. TGFB1 is a key cytokine associated with inflammation and fibrosis, but its role in acute toxicity is unclear. The presence of T allele at −509 bp of the promoter region of TGFB1 gene is related to higher concentrations of TGFB1 than C allele. We aimed to investigate association between C-509T polymorphism (rs1800469) and RT-induced acute toxicity. Patients and methods: Eighty six patients who had a localized or locally advanced PCa were treated with radical (72 Gy)(n=49) or postoperative/salvage (66 Gy)(n=37) RT without previous hormonal therapy. TGFB1 C-509T was determined by PCR-RFLP analysis on DNA from PBMC. The differences in the distribution of genotypes between patients with or without acute genitourinary (GU) or gastrointestinal (GI) toxicity were tested by χ2 and Fisher’s exact test. P values ≤0.05 were considered statistically significant. The genotype-specific associations with toxicity were estimated as odds ratios (OR) with 95% confidence intervals (CIs) for dominant, recessive, codominant and overdominant genetic model. Results: Heterozygote carriers of TGFB1 C-509T had statistically significant lower rate of acute GU and GI toxicity then homozygotes (CC plus TT) (p=0.048; p=0.047). Additionally, the OR indicated lower risk for acute toxicity development in heterozygote than homozygote patients (OR (95%CI) were: 0.12 (0.01- 1.11) for GU and 0.19 (0.03- 1.02) for GI). Conclusion: The obtained data indicate that CT genotype of TGFB1 C-509T could be potential biomarkers of lower risk for acute RT-induced toxicity.",
publisher = "Belgrade : Serbian Association for Cancer Research (SDIR)",
journal = "SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts",
title = "Association between TGFB1 C-509T polymorphism and acute toxicity after radiotherapy for prostate cancer",
pages = "60-60",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12415"
}
Mališić, E., Petrović, N., Nikitović, M.,& Stanojković, T.. (2021). Association between TGFB1 C-509T polymorphism and acute toxicity after radiotherapy for prostate cancer. in SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts
Belgrade : Serbian Association for Cancer Research (SDIR)., 60-60.
https://hdl.handle.net/21.15107/rcub_vinar_12415
Mališić E, Petrović N, Nikitović M, Stanojković T. Association between TGFB1 C-509T polymorphism and acute toxicity after radiotherapy for prostate cancer. in SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts. 2021;:60-60.
https://hdl.handle.net/21.15107/rcub_vinar_12415 .
Mališić, Emina, Petrović, Nina, Nikitović, Marina, Stanojković, Tatjana, "Association between TGFB1 C-509T polymorphism and acute toxicity after radiotherapy for prostate cancer" in SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts (2021):60-60,
https://hdl.handle.net/21.15107/rcub_vinar_12415 .